共 50 条
- [1] AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R MutationsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (27) : 3162 - +Lu, ShunDong, XiaorongJian, HongChen, JianhuaChen, GongyanSun, YupingJi, YinghuaWang, ZipingShi, JianhuaLu, JunguoChen, ShaoshuiLv, DongqingZhang, GuojunLiu, ChunlingLi, JuanYu, XinminLin, ZhongYu, ZhuangWang, ZhehaiCui, JiuweiXu, XingxiangFang, JianFeng, JifengXu, ZhiMa, RuiHu, JieYang, NongZhou, XiangdongWu, XiaohongHu, ChengpingZhang, ZhihongLu, YouHu, YanpingJiang, LiyanWang, QimingGuo, RenhuaZhou, JianyingLi, BaolanHu, ChunhongTong, WanchengZhang, HelongMa, LinChen, YuanJie, ZhijunYao, YuZhang, LongzhenJie, WengLi, WeidongXiong, JianpingYe, Xianwei
- [2] Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Lu, ShunDong, XiaorongJian, HongChen, JianhuaChen, GongyanSun, YupingJi, YinghuaWang, ZipingShi, JianhuaLu, JunguoChen, ShaoshuiZhang, GuojunLv, DongqingLiu, ChunlingLi, JuanYu, XinminLin, ZhongYu, ZhuangWang, ZhehaiCui, Jiuwei
- [3] Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?BRITISH JOURNAL OF CANCER, 2007, 96 (02) : 399 - 399Costa, D. B.Kobayashi, S.
- [4] Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?British Journal of Cancer, 2007, 96 : 399 - 399D B CostaS Kobayashi
- [5] Exploration of aumolertinib in first-line treatment for advanced non-small cell lung cancer patients of performance status 3 with EGFR mutations (19del and L858R)ANNALS OF ONCOLOGY, 2023, 34 : S1705 - S1705Zhou, C.Xie, X.Wu, J.Deng, H.Lin, X.
- [6] Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutationJOURNAL OF THORACIC DISEASE, 2023, 15 (11) : 6115 - +Gilardone, SophiaThapa, RamLaborde, JoseShafique, MichaelSaltos, AndreasCreelan, BenTanvetyanon, TaweeChiappori, AlbertoSimon, GeorgeHaura, Eric B.Gray, Jhanelle E.Chen, Dung-TsaMelzer, DanielPellini, Bruna
- [7] Detecting EGFR exon 19 deletions and L858R in patients with non small cell lung cancerEUROPEAN JOURNAL OF HUMAN GENETICS, 2018, 26 : 582 - 582Hammoudeh, Z. A.Koleva, V.Kyuchukov, Y.Dakova, P.Penev, A.Minchev, T.Toncheva, D.
- [8] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449Sequist, Lecia V.Martins, Renato G.Spigel, DavidGrunberg, Steven M.Spira, AlexanderJaenne, Pasi A.Joshi, Victoria A.McCollum, DavidEvans, Tracey L.Muzikansky, AlonaKuhlmann, Georgiana L.Han, MoonGoldberg, Jonathan S.Settleman, JeffreyIafrate, A. JohnEngelman, Jeffrey A.Haber, Daniel A.Johnson, Bruce E.Lynch, Thomas J.
- [9] The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancerJOURNAL OF CANCER, 2017, 8 (10): : 1865 - 1871Zhang, YaxiongChen, GangChen, XiFang, WenfengGao, FeiYang, YunpengZhao, YuanyuanMa, YuxiangHong, ShaodongZhang, ZhonghanMiao, SiyuWu, ManliHuang, XiaodanLuo, YouliZhou, CongGong, RunHuang, YanChen, LikunZhou, NingningZhao, HongyunZhang, Li
- [10] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation SubgroupsJOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754Wu, Y.Cheng, Y.Zhou, X.Lee, K. H.Nakagawa, K.Niho, S.Tsuji, F.Rosell, R.Corral, J.Migliorino, M. R.Pluzanski, A.Linke, R.Sbar, E.Wang, T.Zhang, H.Mok, T.